Wells Fargo & Company Synaptogenix, Inc. Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$0.16 - $0.3 $1 - $3	10 Added 6.71%	159 $0
Q4 2023 Feb 09, 2024	BUY	$0.23 - $0.4 $22 - $39	99 Added 198.0%	149 $0
Q3 2023 Nov 13, 2023	BUY	$0.28 - $1.04 $0 - $1	1 Added 2.04%	50 $0
Q2 2023 Aug 15, 2023	BUY	$0.78 - $1.0 $2 - $3	3 Added 6.52%	49 $0
Q1 2023 May 12, 2023	BUY	$0.8 - $1.33 $2 - $3	3 Added 6.98%	46 $0
Q4 2022 Feb 13, 2023	SELL	$1.02 - $181.75 $366 - $65,248	-359 Reduced 89.3%	43 $0
Q3 2022 Nov 14, 2022	SELL	$4.6 - $172.25 $18 - $689	-4 Reduced 0.99%	402 $2,000
Q2 2022 Aug 12, 2022	BUY	$3.88 - $7.41 $19 - $37	5 Added 1.25%	406 $2,000
Q1 2022 May 16, 2022	BUY	$6.31 - $10.09 $2,271 - $3,632	360 Added 878.05%	401 $3,000
Q4 2021 Feb 14, 2022	BUY	$8.38 - $13.72 $33 - $54	4 Added 10.81%	41 $0
Q3 2021 Nov 15, 2021	BUY	$6.65 - $12.1 $246 - $447	37 New	37 $0

30K

Ticker SNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 6,840,630
Market Cap $21M
Description
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodeg...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.